MRI Brain — Dedicated Protocol for Tumor Suspicion

Version 1.0 — August 2026

1. Executive Summary

1.1 Added Value over the Generic Protocol

The generic Brain protocol’s T1/T2/FLAIR/DWI/SWI backbone reliably detects the great majority of intracranial mass lesions, but full characterisation, grading, and surgical/radiotherapy planning for a suspected brain tumour requires targeted additions the generic protocol does not include by default: mandatory, parameter-matched pre- and post-contrast 3D T1-weighted imaging (rather than conditional contrast), perfusion imaging (DSC or, where unavailable, an alternative perfusion technique) to help distinguish tumour grade and tumour from mimickers, and a structured approach to reporting that follows the current WHO CNS classification’s grading terminology. This child page follows the internationally consensus-endorsed Brain Tumor Imaging Protocol (BTIP) framework, adapted to routine clinical (rather than clinical-trial) practice.

1.2 Limits of the Dedicated Protocol

MRI characterises tumour location, extent, and imaging phenotype with high sensitivity, but definitive diagnosis — including the molecular subtyping (IDH mutation status, 1p/19q codeletion, MGMT methylation, and other markers) that now forms part of the WHO CNS5 diagnostic framework — requires tissue sampling; imaging findings inform the differential and surgical approach without replacing histopathological and molecular diagnosis. Perfusion- and diffusion-based grading indices are genuinely useful but imperfect: overlap exists between grades and between tumour types, and a small but clinically important proportion of cases (particularly some IDH-mutant, non-enhancing gliomas) do not follow the classic “more aggressive = more perfusion/enhancement” pattern.

2. Clinical Context

2.1 Clinical Presentation

Presentation depends heavily on tumour location and growth rate: a new, unexplained focal neurological deficit, new-onset seizure in an adult (addressed in more sequence-specific depth in the companion Epilepsy child page for chronic/established epilepsy, but relevant here for new-onset presentations specifically raising tumour concern), progressive cognitive or personality change, and headache with red-flag features (papilloedema, worse on waking, progressive) are the principal presentations prompting tumour-specific brain MRI, distinct from the primary/idiopathic headache population addressed in the companion Headache child page.

2.2 Tumour Categories Relevant to Brain MRI

Primary intra-axial tumours (diffuse gliomas across the IDH-mutant/wild-type and 1p/19q-codeletion-defined categories established by WHO CNS5, plus other glial and glioneuronal tumour types), extra-axial tumours (meningioma, vestibular schwannoma and other cranial nerve sheath tumours), and metastatic disease (the most common intracranial malignancy overall in adults) each have distinct typical locations, growth patterns, and imaging phenotypes that this protocol is designed to characterise and, where possible, distinguish.

2.3 Differential Diagnosis (Clinical)

A new mass-like or enhancing lesion on brain MRI is not always neoplastic: the clinical differential specifically includes infection (pyogenic abscess, in particular), demyelinating disease presenting as a tumefactive lesion (addressed in the companion Multiple Sclerosis child page for the more typical presentation), subacute infarction, and — in a patient with a known primary malignancy — treatment-related change versus recurrence, a distinction this protocol addresses directly in Section 5.

3. Indications, Timing, and Patient Selection

3.1 When the Dedicated Protocol Is Indicated

Any new, clinically or incidentally identified intracranial mass lesion; a new unexplained focal neurological deficit or cognitive change with imaging concerning for a mass; known primary CNS tumour requiring pre-treatment characterisation, surgical planning, or post-treatment surveillance; and known extracranial malignancy with new neurological symptoms raising concern for metastatic disease are all indications for this dedicated protocol rather than the generic protocol alone.

3.2 Baseline and Surveillance Imaging

For known tumours under surveillance or post-treatment follow-up, a well-characterised baseline study — ideally following the same protocol parameters at each timepoint — is of substantial value, since response assessment (addressed by the existing RANO 2.0 Glioma Response Assessment deep dive elsewhere on MRIninja) depends on genuine, technically comparable interval comparison rather than a single isolated study.

3.3 Pre-Surgical Planning Considerations

Where surgical resection is being planned, additional sequences beyond the diagnostic core — functional MRI for eloquent cortex localisation and diffusion tensor imaging/tractography for white matter tract mapping — are frequently added at many centres; these advanced, surgical-navigation-integrated techniques are outside the scope of the diagnostic protocol documented in this child page and are addressed by dedicated functional/tractography technique pages elsewhere on MRIninja where available.

3.4 Red Flags Modifying Urgency

Rapidly progressive neurological deficit, signs of raised intracranial pressure (papilloedema, declining consciousness), or new seizure with focal deficit warrant urgent same-day or next-available imaging rather than routine elective scheduling, given the risk of rapid clinical deterioration with some tumour types and the possibility of a treatable acute complication (haemorrhage, significant mass effect, hydrocephalus).

4. Dedicated Protocol Design

4.1 Mandatory Core Sequences

The table below lists the complete mandatory protocol for brain tumour suspicion — the five generic-protocol core sequences (1-5) plus the tumour-specific additions (6-9) detailed in full, including disease-specific purpose, in Section 4.3. See Section 4.2 for the full comparison against the generic protocol.

4.2 Protocol Delta vs the Generic Protocol

4.3 Mandatory Dedicated Sequences — Detail and Disease-Specific Purpose

5. MRI Semiotics of Brain Tumour

5.1 Direct Signs

Enhancement pattern is the single most reported direct sign: a thick, irregular, often necrotic-centred ring of enhancement is classic for high-grade glioma but is also seen in metastasis and, importantly, in pyogenic abscess (Section 5.6); homogeneous, well-defined enhancement with a dural tail favours meningioma; absent or minimal enhancement does not exclude tumour, since a clinically and molecularly important subset of gliomas (particularly some IDH-mutant, lower-grade tumours under the current WHO CNS5 framework) show little or no contrast enhancement.

5.2 Indirect and Secondary Signs

Perilesional T2/FLAIR signal change (vasogenic oedema for most extra-axial and metastatic lesions vs infiltrative, non-enhancing tumour extension for diffuse glioma — a distinction with direct relevance to surgical margin planning), mass effect and midline shift, and susceptibility signal (intratumoral haemorrhage or calcification on SWI/GRE) are all clinically relevant secondary findings that should be documented alongside the primary enhancement pattern.

5.3 Perfusion and Grading-Relevant Imaging Features

Elevated relative cerebral blood volume (rCBV) on DSC perfusion correlates with tumour vascularity and has been shown to help distinguish high-grade from low-grade glial tumours and to help distinguish glial tumours from metastases, with tumoral and peritumoral rCBV both reported as significantly higher in glial tumours than in metastases in direct comparative studies — though rCBV should be interpreted as one contributing feature within the overall imaging and clinical picture, not as a stand-alone diagnostic threshold.

5.4 Relevant Classification Frameworks

Reporting terminology should align with the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5), which established grading and nomenclature changes — including grading diffuse gliomas by integrated histological and molecular criteria rather than histology alone — that materially affect how imaging findings should be framed and communicated to referring clinicians; response assessment in known/treated glioma follows the RANO 2.0 criteria, documented in the existing dedicated deep dive elsewhere on MRIninja rather than repeated here.

5.5 Differential Diagnosis on Imaging

Beyond tumour-versus-tumour-type differentials (Section 5.1), the most clinically important non-neoplastic mimickers are pyogenic brain abscess (Section 5.6), tumefactive demyelination, and subacute infarction — each of which can produce a ring-enhancing or mass-like appearance superficially resembling tumour on standard sequences alone.

5.6 Mimickers and Pitfalls — Abscess vs Necrotic Tumour

Diffusion-weighted imaging is specifically useful in distinguishing pyogenic brain abscess from a necrotic or cystic brain tumour: in the original comparative study establishing this sign, brain abscesses showed markedly hyperintense DWI signal (restricted diffusion, low ADC, reflecting viscous pus) in all patients studied, while necrotic or cystic brain tumours showed hypointense DWI signal (unrestricted diffusion) in all patients studied — a genuinely useful discriminating sign, though it is not infallible, and atypical restricted diffusion has also been reported in occasional necrotic high-grade gliomas, meaning DWI findings should be interpreted alongside clinical context (fever, infective risk factors) rather than in isolation.

6. Reporting Framework

6.1 Structured Reporting Template

Lesion location and laterality: intra-axial vs extra-axial, lobe/structure involved. Size and extent: maximum dimensions, involvement of eloquent structures. Signal characteristics: T1, T2/FLAIR, DWI/ADC, SWI findings. Enhancement pattern: present/absent, homogeneous/heterogeneous/ring, thickness and regularity. Perfusion findings: rCBV pattern, relative to normal white matter. Perilesional change: vasogenic oedema vs infiltrative non-enhancing extension; mass effect and midline shift. Comparison with prior imaging: stable/progressed/new, explicitly stated when a baseline exists.

6.2 Mandatory Reporting Elements

Every report should explicitly state whether a genuine pre-contrast baseline was available for comparison with the post-contrast series (Section 4.3), and should avoid over-interpreting an isolated finding (a single perfusion value, a single restricted-diffusion focus) as diagnostic of a specific entity without integrating it with the full imaging and clinical picture, particularly given the abscess-vs-tumour and grade-overlap pitfalls documented in Section 5.

6.3 Critical/Actionable Findings

Significant mass effect with midline shift, hydrocephalus, or imaging features suggesting impending herniation are critical findings requiring immediate communication; a new finding significantly altering the working diagnosis (e.g. imaging strongly favouring abscess over tumour, or vice versa, given the substantially different management pathways) should also be flagged explicitly and promptly rather than left to routine report turnaround.

6.4 Common Reporting Errors

Reporting enhancement pattern without explicit comment on perfusion findings when perfusion imaging was acquired; describing a “ring-enhancing lesion” without considering and commenting on the abscess-versus-tumour differential when the clinical context does not clearly exclude infection; and omitting explicit comparison with prior imaging in a known surveillance or post-treatment case.

7. Technical Pitfalls

7.1 Contrast Timing Consistency

Because post-contrast T1 signal is the primary sequence for enhancement characterisation, inconsistent timing between contrast injection and image acquisition — across sequential studies in the same patient, or even within a single study if the post-contrast T2 (sequence 7) is omitted or reordered — introduces genuine variability into enhancement assessment; the BTIP-consensus sequence ordering (T2 before T1 post-contrast) exists specifically to standardise this.

7.2 Sequence-Specific Technical Considerations

Perfusion imaging (DSC) technique varies meaningfully in acquisition parameters and post-processing (leakage correction, in particular) across centres and vendors, and absolute rCBV values are not perfectly comparable between different technical implementations — a genuine limitation acknowledged in the perfusion literature and worth bearing in mind when comparing a current study’s perfusion values against a differently-acquired prior study.

7.3 When the Generic Protocol Alone Is Insufficient

A brain MRI performed for suspected tumour using only the generic protocol’s conditional contrast approach, without mandatory parameter-matched pre-/post-contrast imaging and perfusion, risks an incomplete characterisation that does not answer the specific grading and differential questions this indication requires.

8. MRI Technologist Pearls

8.1 Sequence Order Logic

Follow the BTIP-consensus ordering specifically for the contrast-related sequences: pre-contrast 3D T1, then contrast administration, then post-contrast 2D axial T2, then post-contrast 3D T1 — this specific ordering, not simply “acquire contrast sequences at some point,” is what the consensus protocol recommends for timing standardisation.

8.2 Positioning and Planning Considerations

Plan perfusion imaging coverage to genuinely include the full lesion and a reasonable normal-appearing white matter reference region, since rCBV interpretation depends on a valid internal reference comparison, not the lesion signal in isolation.

8.3 Fast Salvage Protocol

If examination time is genuinely constrained, prioritise the mandatory parameter-matched pre-/post-contrast 3D T1 pair (sequences 6 and 8) above perfusion imaging, since enhancement characterisation is more universally interpretable across referring clinicians than perfusion data, even though perfusion adds genuine diagnostic value when time allows.

8.4 Disease-Specific Common Avoidable Errors

Omitting the pre-contrast 3D T1 baseline (making true enhancement assessment impossible); failing to maintain parameter-matching between pre- and post-contrast 3D T1 acquisitions; and omitting perfusion imaging when it was clinically requested or clearly indicated by the differential.

9. Quality Control Checklist

• Pre-contrast and post-contrast 3D T1 sequences confirmed parameter-matched.
• Post-contrast T2 confirmed acquired between contrast injection and post-contrast T1, per BTIP-consensus ordering.
• Perfusion imaging confirmed diagnostic quality, with adequate normal-appearing reference tissue included.
• Prior imaging retrieved and available for direct comparison whenever the clinical question involves surveillance or possible recurrence.
• Report reviewed for explicit comment on both enhancement pattern and perfusion findings, not enhancement alone.

11. Evidence Gaps and Ongoing Debate

• Optimal DSC leakage-correction methodology remains incompletely standardised. As referenced in Section 10, multiple distinct leakage-correction approaches exist (pre-load dosing, post-processing correction algorithms, or both), and the reviewed literature does not describe a single universally adopted best-practice technique, limiting direct cross-site and cross-vendor comparability of absolute rCBV values.
• rCBV-based grading and tumour-type discrimination show genuine, clinically relevant overlap. While tumoral and peritumoral rCBV are reported as significantly higher in glial tumours than metastases in comparative studies, the overlap between individual cases means perfusion should inform, not replace, the overall diagnostic and clinical picture.
• The DWI abscess-vs-necrotic-tumour sign, while well-established, is not infallible. As noted in Section 5.6, atypical restricted diffusion has been reported in occasional necrotic high-grade gliomas, and the original and subsequent studies establishing this sign involved comparatively small patient numbers — a genuinely useful but not perfectly specific discriminator.

12. Evidence-Based References

A. Guidelines / Consensus / Society Recommendations

C. Important Prospective / Original Studies

D. Technical MRI Papers

Represented by the Ellingson et al. 2015 BTIP consensus paper already listed under Category A; a separate, non-duplicative Category D entry is not populated to avoid citing the same source twice.

E. Landmark Historical References

No landmark historical reference specific to brain tumour MRI, distinct from the modern consensus and classification standards already cited, was identified as warranting separate citation. Category E is therefore not populated for this child page.

End of document — MRI Brain — Dedicated Protocol for Tumor Suspicion — Child Protocol under the MRIninja Head / Brain master page — v1.0 — August 2026 Parent page: Brain Generic Standard Protocol